Lixisenatide/Insulin glargine

利司那肽/甘精胰岛素

Report date: 2026/03/04 20:01:44

Base Information

Drug NameLixisenatide/Insulin glargine
Drug Alias Name甘精胰岛素利司那肽注射液インスリン グラルギン•リキシセナチドinsulin glargine + lixisenatideINSULIN GLARGINE +LIXISENATIDELong acting GLP-1 agonist +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsInsulin receptor agonists
TargetsGlucagon-like peptide 1 receptorInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2016/11/21
Country/TerritoryCzechiaBelgiumCanada +[31] 
CombinationsYes LixisenatideInsulin glargine
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesBiogenomicsSanofi KkSanofi-Aventis U.S. Llc +[4] 
Inactive CompaniesSanofi-Aventis GroupeSanofiSanofi-Aventis Deutschland Gmbh +[6] 
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeA10AE54
Related LinksN/A